Matt Franz : Zealous For Knowledge

Inotek Pharmaceuticals

Inotek Pharmaceuticals is a clinical stage biopharmaceutical company whose only drug candidate, trabodenoson, recently failed. In the wake of the drug’s failure Inotek has suspended all R&D activities and hired Perella Weinberg Partners to explore strategic alternatives.

Inotek’s stock currently trades well below its net asset value (NAV), which provides an opportunity for profit should the company liquidate or sell itself.

My full notes and valuation are here.

This is not a recommendation to buy or sell any stock mentioned. I own shares of Inotek Pharmaceuticals. Do your own research: you are accountable for your own returns. Please read my full disclosure.

2 responses to “Inotek Pharmaceuticals”

  1. hot coffee says:

    Howdʏ I am ѕo glad I found your blog, I really found you by mistake, while I was reѕearching on Bing for something
    else, Anyways I am here now and would just like to say thank
    уou for a mɑгvеlous post and a all round enjoyable blog
    (I also love the theme/design), I don’t have time to browse it ɑll
    at the moment but I have ѕaved it and ɑlso added in your
    RSS feeds, so when I have time I will be back to read a great deɑl more, Please do
    keep up the fantastic jo.

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe: rss | email